SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W60390279> ?p ?o ?g. }

Showing items 1 to 100 of ±172 with 100 items per page.

W60390279 endingPage "99" @default.
W60390279 startingPage "83" @default.
W60390279 abstract "The contemporary challenge of prostate cancer diagnosis has been changed in the past decade from the endeavor to increase detection to that of detecting only those tumors that are clinically significant. Better interpretation of the role of prostate-specific antigen (PSA) and its kinetics as a diagnostic tool, the adoption of extended prostate biopsy schemes, and perhaps implementation of new transrectal ultrasound (TRUS) technologies promote the achievement of this clinical mission. This chapter reviews these issues as well as the change in practice of patient preparation for TRUS-biopsy and analgesia during it, the role of repeat and saturation prostate biopsies, and the interpretation of an incidental prostate cancer finding. p ] Currently, the lifetime risk of a diagnosis of prostate cancer for North American men is 16%, compared to the lifetime risk of death from prostate cancer, which is 3% (Carter 2004). The advent of prostate-specific antigen (PSA) screening and transrectal ultrasonography (TRUS) has significantly impacted the detection of prostate cancer over the last 20 years. The mean age at diagnosis has decreased (Hankey et al. 1999; Stamey et al. 2004) and the most common stage at diagnosis is now localized disease (Newcomer et al. 1997; Stamey et al. 2004). The goal of prostate cancer screening is to detect only those men at risk for death from the disease at an early curable phase. The ambiguous natural history of this most common malignancy in men, being latent with questionable life-threatening potential in a large number of cases on the one hand, with only a relatively small number (though not negligible) of highly malignant cases on the other, propels many doubts about whether this is possible. This was famously phrased more than 20 years ago by Whitmore who asked: “Is cure possible for those in whom it is necessary; and is it necessary for those in whom it is possible?” This is probably even more relevant nowadays. During the past decade two factors influenced significantly the increased detection rate of prostate cancer in general and that of clinically insignificant prostate cancers in particular: the widespread use of serum PSA as a screening tool to a large extent and to a lesser though significant extent the application of extended multiple core biopsy schemes (Master et al. 2005). In fact, 75% of men in the United States aged 50 years and older have been screened with the PSA test (Sirovich et al. 2003). Outside of the screening context, which is dealt with in depth in Chap. 5, clinical suspicion of prostate cancer is raised usually by abnormal digital rectal examination (DRE) and/or by abnormal levels of serum PSA. Final diagnosis is achieved only based on positive prostate biopsies. Currently, the lifetime risk of a diagnosis of prostate cancer for North American men is 16%, compared to the lifetime risk of death from prostate cancer, which is 3% (Carter 2004). The advent of prostate-specific antigen (PSA) screening and transrectal ultrasonography (TRUS) has significantly impacted the detection of prostate cancer over the last 20 years. The mean age at diagnosis has decreased (Hankey et al. 1999; Stamey et al. 2004) and the most common stage at diagnosis is now localized disease (Newcomer et al. 1997; Stamey et al. 2004). The goal of prostate cancer screening is to detect only those men at risk for death from the disease at an early curable phase. The ambiguous natural history of this most common malignancy in men, being latent with questionable life-threatening potential in a large number of cases on the one hand, with only a relatively small number (though not negligible) of highly malignant cases on the other, propels many doubts about whether this is possible. This was famously phrased more than 20 years ago by Whitmore who asked: “Is cure possible for those in whom it is necessary; and is it necessary for those in whom it is possible?” This is probably even more relevant nowadays. During the past decade two factors influenced significantly the increased detection rate of prostate cancer in general and that of clinically insignificant prostate cancers in particular: the widespread use of serum PSA as a screening tool to a large extent and to a lesser though significant extent the application of extended multiple core biopsy schemes (Master et al. 2005). In fact, 75% of men in the United States aged 50 years and older have been screened with the PSA test (Sirovich et al. 2003). Outside of the screening context, which is dealt with in depth in Chap. 5, clinical suspicion of prostate cancer is raised usually by abnormal digital rectal examination (DRE) and/or by abnormal levels of serum PSA. Final diagnosis is achieved only based on positive prostate biopsies." @default.
W60390279 created "2016-06-24" @default.
W60390279 creator A5000388470 @default.
W60390279 creator A5000779166 @default.
W60390279 creator A5090975001 @default.
W60390279 date "2007-06-04" @default.
W60390279 modified "2023-10-16" @default.
W60390279 title "Diagnosis of Prostate Cancer" @default.
W60390279 cites W1571849492 @default.
W60390279 cites W1966130692 @default.
W60390279 cites W1968952916 @default.
W60390279 cites W1970442197 @default.
W60390279 cites W1971351241 @default.
W60390279 cites W1971442767 @default.
W60390279 cites W1976638106 @default.
W60390279 cites W1977902668 @default.
W60390279 cites W1979221982 @default.
W60390279 cites W1980899153 @default.
W60390279 cites W1981604066 @default.
W60390279 cites W1983602950 @default.
W60390279 cites W1983994213 @default.
W60390279 cites W1984011786 @default.
W60390279 cites W1987668278 @default.
W60390279 cites W1989863110 @default.
W60390279 cites W1990515674 @default.
W60390279 cites W1990935373 @default.
W60390279 cites W1991351049 @default.
W60390279 cites W1995331646 @default.
W60390279 cites W1995779531 @default.
W60390279 cites W1999270813 @default.
W60390279 cites W2001661313 @default.
W60390279 cites W2003922832 @default.
W60390279 cites W2009495530 @default.
W60390279 cites W2010902574 @default.
W60390279 cites W2013967795 @default.
W60390279 cites W2016510172 @default.
W60390279 cites W2017359766 @default.
W60390279 cites W2018851435 @default.
W60390279 cites W2019893712 @default.
W60390279 cites W2020894889 @default.
W60390279 cites W2022060592 @default.
W60390279 cites W2024961732 @default.
W60390279 cites W2026118996 @default.
W60390279 cites W2029376495 @default.
W60390279 cites W2030141210 @default.
W60390279 cites W2030932979 @default.
W60390279 cites W2032223225 @default.
W60390279 cites W2034633912 @default.
W60390279 cites W2036119304 @default.
W60390279 cites W2036797747 @default.
W60390279 cites W2038178335 @default.
W60390279 cites W2039250830 @default.
W60390279 cites W2042911313 @default.
W60390279 cites W2046952842 @default.
W60390279 cites W2048597588 @default.
W60390279 cites W2051497916 @default.
W60390279 cites W2052220537 @default.
W60390279 cites W2055284487 @default.
W60390279 cites W2055541947 @default.
W60390279 cites W2055992848 @default.
W60390279 cites W2056874076 @default.
W60390279 cites W2057150473 @default.
W60390279 cites W2057469006 @default.
W60390279 cites W2061048203 @default.
W60390279 cites W2062127211 @default.
W60390279 cites W2064026717 @default.
W60390279 cites W2065833882 @default.
W60390279 cites W2067160234 @default.
W60390279 cites W2069222394 @default.
W60390279 cites W2069368767 @default.
W60390279 cites W2073309915 @default.
W60390279 cites W2075424511 @default.
W60390279 cites W2077686421 @default.
W60390279 cites W2085887715 @default.
W60390279 cites W2087358184 @default.
W60390279 cites W2087927571 @default.
W60390279 cites W2091445657 @default.
W60390279 cites W2092905233 @default.
W60390279 cites W2093030736 @default.
W60390279 cites W2094127381 @default.
W60390279 cites W2098423787 @default.
W60390279 cites W2099948048 @default.
W60390279 cites W2100579942 @default.
W60390279 cites W2103263363 @default.
W60390279 cites W2103711855 @default.
W60390279 cites W2107070811 @default.
W60390279 cites W2107474944 @default.
W60390279 cites W2107937173 @default.
W60390279 cites W2110761744 @default.
W60390279 cites W2113216458 @default.
W60390279 cites W2122101164 @default.
W60390279 cites W2140139520 @default.
W60390279 cites W2140687262 @default.
W60390279 cites W2142112926 @default.
W60390279 cites W2142775721 @default.
W60390279 cites W2143073646 @default.
W60390279 cites W2153321327 @default.
W60390279 cites W2160209118 @default.